Zero-order release formulations using a novel cellulose ester

Cellulose

Volumn 14, Issue 1, 2007, Pages 73-83

  Posey Dowty, Jessica D ^a   Watterson, Thelma L ^a   Wilson, A Kent ^a   Edgar, Kevin J ^a   Shelton, Michael C ^a   Lingerfelt, Larry R ^a  

^a EASTMAN CHEMICAL COMPANY   (United States)

Author keywords

CA; CAB; Carboxymethylcellulose acetate; Carboxymethylcellulose acetate butyrate; Carboxymethylcellulose acetate propionate; Carboxymethylcellulose ester; Cellulose acetate; Cellulose acetate butyrate; Cellulose ester; CMCA; CMCAB; CMCAP; Compression tablet; Dissolution; Extended release; Pharmaceutical drug delivery; Zero order release

Indexed keywords

CELLULOSE; DISSOLUTION; DRUG DOSAGE; DRUG PRODUCTS; ESTERS; HYDROPHILICITY; PH; POLYMER BLENDS;

CARBOXYMETHYLCELLULOSE ACETATE; CARBOXYMETHYLCELLULOSE ACETATE BUTYRATE; CARBOXYMETHYLCELLULOSE ACETATE PROPIONATE; CARBOXYMETHYLCELLULOSE ESTER; CELLULOSE ACETATE; CELLULOSE ESTER; PHARMACEUTICAL DRUG DELIVERY;

DRUG DELIVERY;

CELLULOSE ACETATE; DISSOLUTION; DRUG DELIVERY; PH; POLYMER BLEND;

EID: 33947623163     PISSN: 09690239     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10570-006-9079-7     Document Type: Article

References (36)

1. Block J.H. and Beale J.M. (eds) 2004. Wilson and Gisvold's Textbook of Organic and Pharmaceutical Chemistry, 11th ed. Lippincott, Williams and Wilkins, Philadelphia, PA, pp.948-956.
2. Bodmeier R., Siepmann J. (1999) Nondegradable Polymers for Drug Delivery. Encyclopedia of Controlled Delivery. John Wiley and Sons Inc., New York, pp. 670-671
3. Brooks P.M., Roberts M.S., Patel B. (1978) Pharmacokinetics of Sustained Release Aspirin. Br. J. Clin. Pharmacol. 5:337-339
4. Charman W.N., Porter C.H., Mithni S., Dressman J.B. (1997) Physicochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH. J. Pharm. Sci. 86(3):269-282
5. Clark D.N., Mowat A., Brunt P.W. (1977) A comparison of a new slow-release aspirin with plain aspirin in the treatment of rheumatoid disease. J. Int. Med. Res. 5:270-275
6. Coupe A.J., Davis S.S., Wilding I.R. (1991a) Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm. Res. 8(8):360-364
7. Coupe A.J., Davis S.S., Evans D.F., Wilding I.R. (1991b) Correlation of the gastric emptying of nondisintegrating tablets with gastrointestinal motility. Pharm. Res. 8(10):1281-1285
8. Coupe A.J., Davis S.S., Evans D.F., Wilding I.R. (1992) The effect of sleep on the gastrointestinal transit of pharmaceutical dosage forms. Int. J. Pharm. 78:69-76
9. Danckwert M.P. (1994) Development of a zero-order release oral compressed tablet with potential for commercial tabletting production. Int. J. Pharm. 112:37-45
10. Di Francesco V., Zamboni M., Dioli A., Zoico E., Mazzali G., Omizzolo F., Bissoli I., Solerte S.B., Benini L., Bosello O. (2005) Delayed postprandial gastric emptying and impaired gallbladder. Contraction together with elevated cholecystokinin and peptide YY serum levels sustain satiety and inhibit hunger in healthy elderly persons. J. Gerontol. A Biol. Sci. Med. Sci. 60:1581-1585
11. Dressman J.B., Berardi R.R., Dermentozoglou L.S., Russell T.L., Schmaltz S.P., Barnett J.L., Jarvenpaa K.M. (1990) Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm. Res. 7(7):756-761
12. Earl R.T., Jenkins R., Munro A.J. (1996) A double-masked comparison of the efficacy of once-daily sustained-release ibuprofen and once-daily piroxicam for 24-hour control of arthralgia due to osteoarthritis in the elderly. Current Therapeutic Res. 57(10):811-820
13. Faham A., Marechal D. and Chenevier P. 2004. Orodispersible tablets containing fexofenadine. US Patent 6,723,348.
14. Fahmy R., Marnane B., Bensley D. and Hollenbeck R.G. 2002. Dissolution test development for complex veterinary dosage forms: Oral boluses. The AAPS Journal. (Formerly AAPS PharmSci). 4(4) article 35. http://www.aapsj.org/view.asp?art=ps040435
15. Grant, D.J.W. and Higuchi, T. 1990. Section 8.10. Determination of Partition Coefficients. Solubility Behavior of Organic Compounds. John Wiley and Sons, New York. p. 391.
16. Hadgraft J., Valenta C. (2000) pH, pK a and dermal delivery. Int. J. Pharm. 200(2):243-247
17. Hendricken B.A., Felis M.V.S. and Bolger M.B. 2003. The composite solubility versus ph profile and its role in intestinal absorption prediction. The AAPS Journal (formerly AAPS PharmSci): Article 5(1). Article 4. http://www.aapsj.org/view.asp?art=ps050104
18. Hiatt G. 1940. Enteric Coating. US Patent 2,196,768.
19. Jakubowski J.A., Stampfer M.J., Vaillancourt D.F., Deykin D. (1986) Low-dose enteric coated aspirin: A practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase. J. Lab. Clin. Med. 108(6):616-621
20. Jonderko G., Jonderko K., Marcisz C., Golab T. (1997) Gastric emptying in hypothyreosis. Isr. J. Med. Sci. 33(3):198-203
21. Kasim N.A, Whitehouse M., Ramachandran C., Bermejo M., Lennernäs H., Hussain A.S., Junginger H.E., Stavchansky S.A., Midha K.K., Shah V.P., Amidon G.L. (2004) Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol. Pharm. 1(1): 85-96
22. Kim Cherng-ju (1998) Effects of drug solubility, drug loading and polymer molecular weight on drug release from polyox® tablets. Drug Dev. Ind. Pharm. 24(7):645-651
23. Lindenberg M., Kopp S., Dressman J.B. (2004) Classification of orally administered drugs on the world health organization model list of essential medicines according to the biopharmaceutics classification system. Eur. J. Pharm. Biopharm. 58:265-278
24. Lobeck F., Spifiel R.W. (1986) Bioavailability of sustained-release aspirin preparations. Clin. Pharm. 5:236-238
25. Mulder M.H.V., Kruitz F., Smolders C.A. (1982) Separation of isomeric xylenes by pervaporation through cellulose ester membranes. J. Memb. Sci. 11:349-363
26. Obeidat W., Price J.C. (2005) Preparation and in vitro evaluation of prophythiouracil microspheres made of Eudragit RL 100 and cellulose acetate butyrate polymers using the emulsion-solvent evaporation method. J. Microencapsul. 22(3):281-289
27. Palmieri G.F., Michelini S., Di Martino P., Martelli S. (2000) Polymers with ph-dependent solubility: Possibility of use in the formulation of gastro-resistant and controlled-release matrix tablets. Drug Dev. Ind. Pharm. 26(8):837-845
28. Santus G., Baker R.W. (1995) Osmotic drug delivery: A review of the patent literature. J. Control. Release 35:1-21
29. Shelton M.C., Lingerfelt L.R. Jr., Klein S., Posey-Dowty J.D., Edgar K.J., Dressman J.B. 2006. Improved dissolution of glyburide by formation of CMCAB/glyburide solid dispersions. Un published work
30. United States Pharmacopeia and National Formulary 2005: USP 28/NF 23. 2005a. Section NF 23. United States Pharmacopeial Convention, Inc. Rockville, MD, pp. 2981-2985.
31. United States Pharmacopeia and National Formulary 2005: USP 28/NF 23, 2005b. Buffer solutions. United States Pharmacopeial Convention, Inc. Rockville, MD, pp. 2854-2855.
32. United States Pharmacopeia and National Formulary 2005: USP 28/NF 23. 2005c. Section < 711 > Dissolution. United States Pharmacopeial Convention, Inc. Rockville, MD, p. 2413
33. Watkinson A.C., Brain K.R., Walters K.A. (1993) The Penetration of Ibuprofen through Human Skin in vitro: Vehicle, Enhancer and pH Effects. In: Brain K.R., James V. and Walters K.A. (eds), Prediction of percutaneous penetration, Vol. 3B. STS Publishing, Cardiff, UK, pp. 335-341.
34. Wilding I.R., Coupe A.J., Davis S.S. 2001. The role of γ-scintigraphy in oral drug delivery. Adv. Drug Deliv. Rev. 46:103-124
35. Wu Chi-Yuan, Benet L.Z. (2005) Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22(1):11-23
36. Zambito Y., Di Colo G. (2003) Preparation and in vitro evaluation of chitosan matrices for colonic controlled drug delivery. J. Pharm. Pharm Sci. 6(2):274-281